Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

BACKGROUND: Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation. Claims data on persistence may be informative of real-world treatment outcome. This analysis described...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Timothy, Zhdanava, Maryia, Pilon, Dominic, Shah, Aditi, Hilts, Annalise, Lefebvre, Patrick, Feldman, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060501/
https://www.ncbi.nlm.nih.gov/pubmed/36929120
http://dx.doi.org/10.1007/s13555-023-00910-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060501/
https://www.ncbi.nlm.nih.gov/pubmed/36929120
http://dx.doi.org/10.1007/s13555-023-00910-6

Ejemplares similares